1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

J&J/Legend Tout Carvykti In Earlier Lines As Competitors Move In

 
• By Alaric DeArment

They have new data for the CAR-T after one to three lines of multiple myeloma treatment and Phase III patient-reported outcomes data, but Gilead and Gracell are nipping at the companies’ and BMS’s heels.

• Source: Scrip

Johnson & Johnson and Legend Biotech Corp. are working to position their BCMA-directed chimeric antigen receptor T-cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel), in earlier lines of treatment, while also highlighting its benefits from patients’ perspectives, at a time when the market for multiple myeloma CAR-T therapies is becoming increasingly competitive.

The two companies presented new Carvykti data at the American Society of Hematology (ASH) meeting, which ended on 12 December in San Diego, including results for patients treated in earlier-line...

Key Takeaways

  • J&J and Legend Biotech presented Phase II and Phase III data for Carvykti in earlier lines of multiple myeloma therapy.

  • BMS and 2seventy...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

More from Anticancer

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.